Advances in PSMA-Targeted Radionuclide Therapeutics.

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2025-04-01 Epub Date: 2025-03-26 DOI:10.1007/s11864-025-01296-7

Samuel Ruder, Andres Ricaurte-Fajardo, Michael Sun, Sandra Huicochea Castellanos, Joseph R Osborne, Scott T Tagawa

{"title":"Advances in PSMA-Targeted Radionuclide Therapeutics.","authors":"Samuel Ruder, Andres Ricaurte-Fajardo, Michael Sun, Sandra Huicochea Castellanos, Joseph R Osborne, Scott T Tagawa","doi":"10.1007/s11864-025-01296-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>Prostate-specific membrane antigen targeted radionuclide therapies (PSMA-TRT) such as 177Lu-PSMA-617 hold great promise in improving clinical outcomes at various stages of prostate cancer. The FDA approval of 177Lu-PSMA-617 represents a significant advancement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The VISION trial demonstrated improved radiographic progression-free survival (rPFS) and overall survival (OS) with 177Lu-PSMA-617 in patients with mCRPC who had already receive androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy. Exploration of 177Lu-PSMA-617 in earlier stages of prostate cancer, such as in the PSMAfore trial for patients who have not received chemotherapy, holds great promise for improving long-term outcomes and delaying exposure to chemotherapy. Combining 177Lu-PSMA-617 with other therapies, including chemotherapy, PARP inhibitors, and immunotherapy, is an area of active investigation. This review will also discuss alternative radionuclides (such as actininum-225 and terbium-161) and delivery vehicles (such as PSMA-I&T), which we find promising. Predictive biomarkers and dosimetry will be crucial for identifying patients most likely to benefit from PSMA-TRT. Continued research and refinement of these therapies will lead to PSMA-targeted treatments becoming an integral part of prostate cancer management.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"291-301"},"PeriodicalIF":3.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-025-01296-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: Prostate-specific membrane antigen targeted radionuclide therapies (PSMA-TRT) such as 177Lu-PSMA-617 hold great promise in improving clinical outcomes at various stages of prostate cancer. The FDA approval of 177Lu-PSMA-617 represents a significant advancement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The VISION trial demonstrated improved radiographic progression-free survival (rPFS) and overall survival (OS) with 177Lu-PSMA-617 in patients with mCRPC who had already receive androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy. Exploration of 177Lu-PSMA-617 in earlier stages of prostate cancer, such as in the PSMAfore trial for patients who have not received chemotherapy, holds great promise for improving long-term outcomes and delaying exposure to chemotherapy. Combining 177Lu-PSMA-617 with other therapies, including chemotherapy, PARP inhibitors, and immunotherapy, is an area of active investigation. This review will also discuss alternative radionuclides (such as actininum-225 and terbium-161) and delivery vehicles (such as PSMA-I&T), which we find promising. Predictive biomarkers and dosimetry will be crucial for identifying patients most likely to benefit from PSMA-TRT. Continued research and refinement of these therapies will lead to PSMA-targeted treatments becoming an integral part of prostate cancer management.

查看原文本刊更多论文

psma靶向放射性核素治疗的研究进展。

观点声明：前列腺特异性膜抗原靶向放射性核素疗法（PSMA-TRT），如177Lu-PSMA-617，在改善前列腺癌不同阶段的临床结果方面具有很大的希望。FDA批准177Lu-PSMA-617在转移性去势抵抗性前列腺癌（mCRPC）治疗方面取得了重大进展。VISION试验表明，在已经接受雄激素受体途径抑制剂（ARPI）和紫杉烷化疗的mCRPC患者中，使用177Lu-PSMA-617可改善放射学无进展生存期（rPFS）和总生存期（OS）。探索177Lu-PSMA-617在早期前列腺癌中的作用，例如在未接受化疗的患者的PSMAfore试验中，有望改善长期预后并延迟化疗时间。将177Lu-PSMA-617与其他疗法（包括化疗、PARP抑制剂和免疫疗法）联合使用是一个积极研究的领域。本文还将讨论替代放射性核素（如锕-225和铽-161）和运载工具（如PSMA-I&T），我们认为这是有前途的。预测性生物标志物和剂量测定对于确定最有可能从PSMA-TRT中获益的患者至关重要。这些疗法的持续研究和改进将导致psma靶向治疗成为前列腺癌治疗的一个组成部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.